Catalyst calendar
Data as of 2026-08-19 16:00 UTC · tracked universe polled every 15 minutes
Three kinds of date: a PDUFA date (the deadline the FDA sets itself to decide on a drug application), an AdCom (an FDA advisory-committee meeting that reviews it in public), and a readout window (when a trial's results are expected). Dates marked confirmed by the company come from an 8-K or press-release quote; our estimate is a rule-derived window off the trial's registered primary-completion date (see methodology) — never shown the same way. Today: 200 estimated readout windows and 0 disclosed PDUFA/AdCom dates.
Next 7 days
| Date | Ticker | Phase | Event |
|---|---|---|---|
| 2026-08-24 in 5d | $REGN | Phase 2 | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy… NCT06161441 |
| 2026-09-23 in 5w | $PFE | Phase 2 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With… NCT04557449 |
| 2026-09-28 in 6w | $INCY | Phase 2 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous… NCT05888844 |
| 2026-09-30 in 6w | $MRTX | Phase 2 | Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS… NCT05609578 |
| 2026-09-30 in 6w | $ARGX | Phase 2 | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of… NCT06392386 |
| 2026-10-19 in 9w | $PFE | Phase 2 | A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In… NCT05995964 |
| 2026-10-20 in 9w | $BIIB | Phase 2 | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve… NCT05531565 |
| 2026-10-30 in 10w | $MRTX | Phase 2 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation… NCT05853575 |
| 2026-10-31 in 10w | $AMGN | Phase 2 | A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced… NCT06593522 |
| 2026-11-02 in 11w | $REGN | Phase 2 | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than… NCT06190951 |
| 2026-11-05 in 11w | $INCY | Phase 2 | Rollover Study to Provide Continued Treatment for Participants With B-Cell… NCT04509700 |
| 2026-11-13 in 12w | $REGN | Phase 2 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity… NCT07431086 |
| 2026-11-20 in 13w | $INCY | Phase 2 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in… NCT05851443 |
| 2026-12-03 in 15w | $REGN | Phase 2 | A Study to Test the Safety, Tolerability, and Efficacy of an Antibody,… NCT06421636 |
| 2026-12-29 in 19w | $REGN | Phase 2 | A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult… NCT07477704 |
| 2026-12-30 in 19w | $VRTX | Phase 2 | Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With… NCT06794996 |
| 2026-12-31 in 19w | $BPMC | Phase 2 | Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous… NCT06931405 |
| 2027-02-09 in 25w | $REGN | Phase 2 | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With… NCT07175428 |
| 2027-03-16 in 30w | $ITCI | Phase 2 | Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized… NCT06480383 |
| 2027-03-25 in 31w | $VRTX | Phase 2 | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic… NCT06619860 |
| 2027-04-13 in 34w | $AMGN | Phase 2 | Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum… NCT05549258 |
| 2027-04-27 in 36w | $INCY | Phase 2 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer… NCT07023627 |
| 2027-04-30 in 36w | $ARGX | Phase 2 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous… NCT04280718 |
| 2027-05-28 in 40w | $ALNY | Phase 2 | A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2… NCT07465224 |
| 2027-06-01 in 41w | $INCY | Phase 2 | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With… NCT06388564 |